Loading
A phase 2 trial of Lurbinectedin, Durvalumab in small-cell lung cancer, run by Jazz Pharmaceuticals, now recruiting.
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC is a phase 2 interventional study registered as NCT07459634 by Jazz Pharmaceuticals, with 50 participants planned, started 2026-11-30 and due to reach its primary completion in 2028-01-31. Interventions recorded: Lurbinectedin, Durvalumab. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lurbinectedin, Jazz Pharmaceuticals, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Lurbinectedin, Jazz Pharmaceuticals, Cytotoxic chemotherapy.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Lurbinectedin, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Extensive-stage small-cell lung cancer, Durvalumab, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/